iX Biopharma has narrowed its loss for the year ended June 30 by 22% to $8.2 million, thanks to better gross margins and higher sales of $1.7 million, up 77% over the preceding FY2020.

The company’s top-line was boosted by robust demand for its nutraceutical products and WaferiX-based product development services from pharmaceutical companies in China. 

The company was able to achieve this even though there were periods of border closures in Australia during the financial year, which impeded its plans to expand its manufacturing capacity and led to constraints on its production capacity. 

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook